

**Gastric and small intestinal motor
function in health and disease –
implications for glucose absorption,
incretin hormone release, and
postprandial blood glucose
regulation**

A thesis submitted by

**Dr. Paul Kuo
MBBS**

For the degree of

Doctor of Philosophy

**Discipline of Medicine
University of Adelaide**

December 2009

Table of contents

Summary	10
Declaration	17
Acknowledgements	18
Publications arising from this thesis	21
Chapter 1: Normal physiology of the upper gut	
1.1 Introduction	24
1.2 Motor function of the stomach and proximal small intestine	26
1.2.1 Proximal stomach	26
1.2.2 Distal stomach	27
1.2.3 Pylorus	27
1.2.4 Duodenum	28
1.2.5 Gastric emptying and its regulation	30
1.2.6 Transpyloric flow	32
1.2.7 Small intestinal transit	33
1.2.8 Gastroduodenal motility	34
1.2.8.1 Fasting motility	34
1.2.8.2 Postprandial motility	35
1.3 Neurohormonal regulation of upper gut function	36
1.3.1 The brain-gut axis	36
1.3.1.1 The enteric nervous system	38
1.3.1.2 Nitric oxide	40
1.3.2 Incretin hormones	42

	1.3.2.1	GLP-1	44
	1.3.2.2	GIP	49
1.4	Sensory function		50
1.5	Conclusion		51

Chapter 2: Gastroduodenal function in diabetes

2.1	Introduction		54
2.2	Glycaemic control and diabetic complications		55
2.3	Upper gut function in diabetes mellitus		56
	2.3.1	Influence of gastric emptying on postprandial glycaemia	58
	2.3.2	Influence of glycaemia on upper gut function	60
2.4	Incretin hormones in diabetes		63
2.5	Diabetic gastropathy		65
	2.5.1	Definition	65
	2.5.2	Pathophysiology	66
	2.5.3	Clinical manifestations	68
	2.5.4	Investigations	70
	2.5.4.1	Measurements of gastric emptying	71
	2.5.5	Management	74
	2.5.5.1	Dietary modification	74
	2.5.5.2	Medical therapy	75
	2.5.5.3	Gastric electrical stimulation	86
	2.5.5.4	Gastrostomy/jejunostomy	88
	2.5.5.5	Surgical therapy	88
2.6	Conclusion		89

Chapter 3: Exocrine pancreatic insufficiency, gastric emptying, and glycaemic control in cystic fibrosis

3.1	Introduction	92
3.2	Pancreatic enzyme replacement therapy	93
3.3	Gastric emptying in cystic fibrosis	96
3.4	Cystic fibrosis-related diabetes	97
	3.4.1 Definition	97
	3.4.2 Pathogenesis	98
	3.4.3 Glucose tolerance	99
	3.4.4 Prognostic implications	100
	3.4.5 Treatment	102
3.5	Relationships between gastric emptying, pancreatic enzyme replacement, and glycaemic control	103
3.6	Conclusion	105

Chapter 4: Techniques in assessing upper gut function

4.1	Introduction	106
4.2	Gastric emptying	106
	4.2.1 Scintigraphy	106
	4.2.2 Three-dimensional ultrasound	108
4.3	Antropyloroduodenal motility	111
	4.3.1 Manometry	111
4.4	Flow events	114
	4.4.1 Impedance monitoring	114
4.5	Upper gut symptom questionnaire	118
	4.5.1 Visual analogue scale (VAS)	118
4.6	Conclusion	118

Chapter 5: Methodologies

5.1	Introduction	119
5.2	Subjects	119
5.3	Ethical approval	120
5.4	Study environment	121
5.5	Drugs	121
	5.5.1 metoclopramide	121
5.6	Glycaemic clamp	122
5.7	Autonomic function testing	123
5.8	Biochemical/hormonal measurements	124
	5.8.1 Blood glucose	125
	5.8.2 Incretin hormones	125
	5.8.2.1 GLP-1	125
	5.8.2.2 GIP	126
	5.8.3 Insulin	126
	5.8.4 3-O-methyl glucose	126
	5.8.5 ¹⁴C-3-O-methyl glucose	127
5.9	Statistical analysis	127
5.10	Conclusion	128

Chapter 6: Validation of ¹⁴C-3-O-methylglucose as a measure of intestinal glucose absorption in humans

6.1	Summary	129
6.2	Introduction	130
6.3	Methods	131
	6.3.1 Subjects	131
	6.3.2 Protocol	131
	6.3.3 Measurements	132
	6.3.4 Statistical analysis	133

6.4	Results	134
6.4.1	Blood glucose concentrations	134
6.4.2	Plasma 3-O-methylglucose (3-OMG) and ^{14}C -3-O methylglucose (^{14}C -3-OMG)	134
6.4.3	Correlations between plasma 3-OMG concentrations, plasma ^{14}C -3-OMG activities, and blood glucose concentrations	135
6.5	Discussion	135

Chapter 7: Transient, early release of glucagon-like peptide-1 during low rates of intraduodenal glucose delivery

7.1	Summary	139
7.2	Introduction	140
7.3	Methods	141
7.3.1	Subjects	141
7.3.2	Protocol	142
7.3.3	Measurements	143
7.3.4	Statistical analysis	143
7.4	Results	144
7.4.1	Blood glucose, insulin, GLP-1 and GIP concentrations	144
7.5	Discussion	145

Chapter 8: Effects of metoclopramide on duodenal motility and flow events, glucose absorption, and incretin hormone release, in response to intraduodenal glucose infusion

8.1	Summary	150
8.2	Introduction	151

8.3	Methods	154
	8.3.1 Subjects	154
	8.3.2 Protocol	154
	8.3.3 Measurements	156
	8.3.4 Statistical analysis	158
8.4	Results	159
	8.4.1 Duodenal pressure waves	159
	8.4.2 Duodenal flow events	160
	8.4.3 Blood glucose and ^{14}C -3-OMG concentrations	160
	8.4.4 Plasma insulin, GIP, and GLP-1 concentrations	161
	8.4.5 Relationships between flow events, pressure waves, glucose absorption, and plasma hormones	163
8.5	Discussion	164

Chapter 9: Effects of physiological hyperglycaemia on duodenal motility and flow events, glucose absorption, and incretin hormone secretion in healthy humans

9.1	Summary	174
9.2	Introduction	175
9.3	Methods	177
	9.3.1 Subjects	177
	9.3.2 Protocol	177
	9.3.3 Measurements	179
	9.3.4 Statistical analysis	182
9.4	Results	182
	9.4.1 Blood glucose concentrations	183
	9.4.2 Duodenal pressure waves	183
	9.4.3 Duodenal flow events	183
	9.4.4 ^{14}C -3-OMG, insulin, GLP-1 and GIP concentrations	184

9.4.5	Relationships between plasma ^{14}C -3-OMG, insulin, GLP-1, and GIP concentrations	186
9.5	Discussion	187

Chapter 10: The nitric oxide (NO) synthase inhibitor, NG-nitro-L-arginine-methyl-ester (L-NAME), attenuates the delay in gastric emptying induced by hyperglycaemia in healthy humans

10.1	Summary	196
10.2	Introduction	197
10.3	Methods	199
	10.3.1 Subjects	199
	10.3.2 Protocol	199
	10.3.3 Measurements	201
	10.3.4 Statistical analysis	204
10.4	Results	205
	10.4.1 Blood pressure and heart rate	205
	10.4.2 Gastric emptying and intragastric distribution	206
	10.4.3 Antral pressure waves	207
	10.4.4 Duodenal pressure waves	208
	10.4.5 Isolated pyloric pressure waves and basal pyloric Pressures	209
	10.4.6 Plasma insulin and GIP concentrations	209
10.5	Discussion	210

Chapter 11: Gastric emptying in cystic fibrosis – implications for management of exocrine pancreatic insufficiency and postprandial glycaemia

11.1	Summary	222
11.2	Introduction	223
11.3	Methods	225
	11.3.1 Subjects	225
	11.3.2 Protocol	226
	11.3.3 Measurements	227
	11.3.4 Statistical analysis	229
11.4	Results	230
	11.4.1 Gastric emptying	231
	11.4.2 Blood glucose	232
	11.4.3 Plasma insulin, GLP-1, and GIP concentrations	234
	11.4.4 Gastrointestinal symptoms	237
11.5	Discussion	238
	Chapter 12: conclusions	249
	Bibliography	254

Thesis summary

The human digestive tract is a complex system that, in addition to the digestion and absorption of nutrients, serves an important neuroendocrine role. The focus of this thesis is to examine how changes in the motor function of the gastroduodenal region influence glucose absorption, gut hormone secretion, and postprandial blood glucose regulation, in different human populations, including the healthy young and those with cystic fibrosis. The studies included utilise a mix of established and novel techniques to evaluate gastroduodenal motor function and glucose absorption, and provide insights into the function of the human gut.

Strict overall glycaemic control dramatically reduces the incidence and progression of micro-, and probably macrovascular, complications associated with type 1 and type 2 diabetes. Postprandial glycaemia is now recognised as an important determinant of overall glycaemia, as indicated by the glycated haemoglobin (HbA1c). The rate of glucose absorption after a meal has a major influence on postprandial glycaemia and has, therefore, been a focus of increasing research interest in recent years. Postprandial blood glucose concentrations are a poor indicator of glucose absorption due to peripheral glucose uptake and hepatic glucose release. The glucose analogue 3-O-methylglucose (3-OMG) is absorbed in the small intestine by the same mechanism as glucose, but is not metabolised, and its plasma concentrations are widely used as an index of glucose absorption. However, analysis of plasma 3-OMG concentrations requires chromatographic

methods which are labour-intensive and costly. By labeling 3-OMG with the ^{14}C radioisotope, plasma ^{14}C -3-OMG activity can be measured by the rapid and inexpensive method of liquid scintillation counting. In Chapter 6, plasma ^{14}C -3-OMG activity was shown to correlate closely to plasma concentrations of 3-OMG, after concomitant oral administration. ^{14}C -3-OMG therefore represents a convenient alternative to 3-OMG, for measuring enteral glucose absorption.

The incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are secreted by the L and K cells in the intestines respectively, in response to nutrient-gut interactions. Their main function is the augmentation of glucose-induced insulin release from the pancreas, the so-called “incretin effect”. GLP-1 also possesses a potent inhibitory effect on gastric emptying, arguably the dominant mechanism through which GLP-1 lowers postprandial blood glucose. However, unlike GIP, the release of which is roughly proportional to the amount of glucose entering the small intestine, a caloric threshold of 1.8 kcal/min has been reported to exist for the release of GLP-1, below which the GLP-1 secretory mechanism is not stimulated. In the study described in Chapter 7, by performing a retrospective analysis of data collated from several studies performed previously, a transient, early release of GLP-1, in response to intraduodenal glucose delivery at the rate of 1 kcal/min, was demonstrated. While the functional significance of this observation remains uncertain, this early release of GLP-1 might serve the role of “priming” the glucoregulatory system, in anticipation for the subsequent arrival of a larger nutrient

load. Furthermore, the mechanism for this early, transient release of GLP-1 remains to be further investigated, as the GLP-1 secreting intestinal L-cells are located most densely in the distal, rather than the proximal, small intestine.

It is established that differences in the rate of gastric emptying contribute to approximately one-third of the variation in the initial rise in postprandial glycaemia, but the contribution made by duodenal motor activity is much less well defined. An increase in duodenal motility, as measured by the number of pressure waves and propagated pressure wave sequences, has been shown to be associated with increased glucose absorption. More recently, using a combined manometry and impedance monitoring technique, it has been demonstrated that duodenal flow events may be a more important determinant of glucose absorption than pressure waves. Impedance monitoring is capable of measuring intraluminal movement of both fluid and air, and can be used in the proximal small intestine to measure the flow of intraluminal chyme. Compared to manometry, impedance monitoring correlates better with fluoroscopy, for measuring movement of small intestinal intraluminal content. In Chapter 8, it was demonstrated that despite stimulating duodenal pressure waves pharmacologically, using the prokinetic agent metoclopramide, there was no concomitant increase in the number of duodenal flow events, as measured by impedance monitoring, and no associated change in glucose absorption. These findings are consistent with those of a previous study using the anti-motility agent, hyoscine butylbromide, and both reinforce the importance of duodenal flow events in determining glucose

absorption, and highlight the value of combining impedance monitoring with manometry in assessing small intestinal motor function and nutrient absorption.

Delayed gastric emptying affects up to 50% of outpatients with long-standing type 1 and type 2 diabetes, often causing persistent upper gut symptoms that are difficult to manage. Acute hyperglycaemia, in a dose-dependent manner, exerts a number of reversible effects on upper gut motor function, including relaxation of the gastric fundus, suppression of antral motility, stimulation of pyloric contractions, and slowing of gastric emptying. In contrast to gastric motor function, data regarding the effects of hyperglycaemia on small intestinal motor function are scarce. Furthermore, there is little information regarding the effects of hyperglycaemia on incretin hormone release and intestinal glucose absorption. The study described in Chapter 9, using the combined manometry and impedance monitoring technique, demonstrated that acute hyperglycaemia in the physiological postprandial range (~9 mmol/L) had minimal impact on duodenal pressure waves and flow events, but reduced fasting plasma GLP-1 concentrations, and increased postprandial GIP secretion and small intestinal glucose absorption. The mechanism for these observations remains to be determined, but may involve changes in the small intestinal mucosa related to hyperglycaemia.

Nitric oxide is a major inhibitory neurotransmitter in the gut, and an increase in its availability has effects on gastropyloric motility and gastric emptying that are

similar to those observed during acute hyperglycaemia. Therefore, nitric oxide may be a mediator of the effects of hyperglycaemia on upper gut motor function. Using the specific nitric oxide synthase inhibitor, NG-nitro-L-arginine-methylester (L-NAME), the study described in Chapter 10 demonstrated that the delay in gastric emptying induced by acute hyperglycaemia (~15 mmol/L) was indeed mediated by nitric oxide, and may involve the modulation of tonic pyloric activity. In addition, nitric oxide may be involved in the release of insulin.

Cystic fibrosis (CF) affects approximately 1 in 2,500 live births in western societies, and the life-expectancy of these patients has risen dramatically as a result of improved medical care. However, this is accompanied by a rapid rise in many long term co-morbidities such as diabetes, which affects ~75 % of all CF patients by the age of 30. Cystic fibrosis-related diabetes (CFRD) is distinct from type 1 and type 2 diabetes, and is characterised by postprandial, rather than fasting, hyperglycaemia. Persistent fat malabsorption occurs in up to 20 % of CF patients, despite pancreatic enzyme supplementation, and fat malabsorption is known to accelerate gastric emptying in both healthy subjects and type 2 diabetes patients. The breakdown of fat is also required to stimulate the release of incretin hormones from the gut. Therefore, fat digestion in CF may be an important factor in determining the rate of gastric emptying and incretin hormone secretion, and consequently, postprandial glycaemia. The study described in Chapter 11 demonstrated that without pancreatic enzyme supplementation, CF patients had more rapid gastric emptying, reduced incretin hormone secretion, and exaggerated

postprandial glycaemic excursions compared to healthy subjects, after a solid high fat, high carbohydrate meal, and that these abnormalities were either substantially improved or normalised by pancreatic enzyme supplementation. Furthermore, the failure of enzyme supplementation to normalise GIP secretion, as opposed to the complete restoration of the GLP-1 response, suggests that mixing of enzymes with food in the proximal small intestine, where GIP-secreting K cells are predominantly located, is suboptimal. Therefore, strategies to optimise mixing between food and enzymes in the proximal small intestine, or incretin-based approaches such as the administration of GIP analogues, represent potential novel approaches in the management of postprandial hyperglycaemia and diabetes in CF.

The recent rapid rise in the prevalence of type 2 diabetes, and the importance of good overall glycaemic control in reducing the long term complications of diabetes, has prompted intense research into new ways to optimise diabetes management. Gastroduodenal motor function has a major influence on glucose absorption, incretin hormone secretion, and postprandial glycaemia, and thus represents an ideal therapeutic target, illustrated by the recent development of GLP-1-based therapies (such as the GLP-1 analogue exenatide, and the DPP-IV inhibitor sitagliptin) for the treatment of type 2 diabetes. However, many areas are still incompletely understood. Further studies are warranted to investigate the relationships between gastroduodenal motor function, glucose absorption, and

incretin hormone secretion, and their impact on postprandial blood glucose regulation.

Declaration

Name..... Program.....

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give my consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australian Digital Thesis Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Signature.....Date.....

Acknowledgements

The first people I would like to thank are my supervisors Assoc Prof Chris Rayner, Prof Michael Horowitz, and Assoc Prof Karen Jones, all of whom have helped me greatly over the four years of my PhD. I consider myself extremely fortunate to have three such great supervisors who are genuine, approachable, kind, professional, and inspirational. They have themselves set excellent examples for me to follow, and their constant encouragements have been instrumental in helping me getting through the tougher times. From these great leaders, I have learnt a tremendous amount not only about medical research, but also about many other aspects of life that helped to shape my professional and personal development. Special mention must go to my principal supervisor Assoc Prof Chris Rayner, who has spent so much of his precious time and energy helping and guiding me, and has always made himself available whenever I needed any help or advice, regardless of his own numerous other commitments.

I would also like to thank my fellow co-workers and colleagues in the Discipline of Medicine of the University of Adelaide, many of whom I have got to know very well over the years, and they have provided me with so much help and support along the way, as well as offering their valuable friendship. They are: Dr. Diana Gentilcore, Miss Lora Vanis, Ms. Ixchel Brennan, Dr. Jing Ma, Dr. Reawika Chaikomin, Ms. Antonietta Russo, Ms. Anne Maddox, Miss Julie Stevens, Ms. Franca Scopacasa, Ms. Judith Wishart, Ms. Kylie Lange, Miss

Nivasinee Nair, Miss Yan Lam, Miss Radhika Seimon, Ms. Angela Hammond, Miss Amelia Pilichiewicz, Mr. George Hatzinikolas, Mr. Paul Cavuoto, Ms. Sue Rogers, Miss Melanie Richards, and Ms. Emily Wooldridge.

On ward Q7 in the Department of Gastroenterology and Hepatology at the Royal Adelaide Hospital, I would like to thank Assoc Prof Richard Holloway for his ongoing encouragement and support, and also Miss Carly Burgstad, Ms. Laura Bryant, Mr. Marcus Tippet, Ms. Dora DiMatteo, Ms. Katrina Ching, Ms. Lee-Anne Faraguna, and all of the nursing staff, for all their help and tolerance while I conducted many experimental studies there. Many thanks also go to the staff members at the Department of Nuclear Medicine, PET, and Bone Densitometry at the Royal Adelaide Hospital, particularly Mr. Max Bellon, who has provided me with plenty of assistance on numerous fronts.

I was also very fortunate to acquire valuable gastric ultrasound skills by learning from some of the most excellent experts in the world, including Prof Odd Helge Gilja and Prof Trygve Hausken, and I would like to thank them for their great teaching and also the warm hospitality that they have shown during my laboratory visit to their institution in Bergen, Norway, in November 2008. Prof Andre Smout from the Netherlands is another distinguished guest from overseas who has provided me with plenty of help, particularly concerning my studies involving impedance monitoring in the small bowel.

Finally, I would like to thank my parents for all their help and support over the many years. Being the closest persons to me, their emotional support was invaluable, and their financial support was also greatly appreciated.

Prior to starting this PhD, I was always confident that this will be a success, simply because of the people I knew I would be working with. Now, looking back at the end of this journey, I realise the experience has far exceeded my wildest expectations. The opportunities to travel interstate and abroad to present our group's works in major national and international meetings were a real eye opener and a fantastic experience that will never be forgotten. What really surprised me, however, was the personal development that I have gained over these years, and I attribute a major part of this to working with such a wonderful group of extraordinary people. All in all, my experiences over the four years of my PhD at the Discipline of Medicine have been so invaluable to me that I would not exchange them with anything else in this world!

Publications arising from this thesis

The materials in this thesis formed the basis for the publications listed below:

Kuo P, Rayner CK, Jones KL, and Horowitz M. Pathophysiology and Management of Diabetic Gastropathy: A Guide for Endocrinologists. *Drugs* 2007;67(12):1671-87.

Kuo P, Rayner CK, and Horowitz M. Gastric emptying, diabetes, and aging. *Clinics in Geriatric Medicine* 2007;23(4):785-808.

Kuo P, Chaikomin R, Pilichiewicz A, O'Donovan D, Wishart JM, Meyer JH, Jones KL, Feinle-Bisset C, Horowitz M, and Rayner CK. Transient, early release of glucagon-like peptide-1 during low rates of intraduodenal glucose delivery. *Regulatory Peptides* 2008;7;146(1-3):1-3.

Kuo P, Gentilcore D, Nair N, Stevens JE, Hausken T, Gilja OH, Wishart JM, Lange K, Horowitz M, Jones KL, and Rayner CK. The nitric oxide (NO) synthase inhibitor, NG-nitro-L-arginine-methyl-ester (L-NAME), attenuates the delay in gastric emptying induced by hyperglycaemia in healthy humans. *Neurogastroenterol Motil* 2009;21(11):1175-e103.

Kuo P, Bellon M, Wishart JM, Smout AJ, Holloway RH, Fraser RJ, Horowitz M, Jones KL, Rayner CK. Effects of metoclopramide on duodenal motility and flow events, glucose absorption, and incretin hormone release, in response to intraduodenal glucose infusion. (Submitted for publication)

Kuo P, Stevens JE, Russo A, Maddox A, Wishart JM, Jones KL, Greville HW, Hetzel DJ, Chapman IM, Horowitz M, and Rayner CK. Gastric emptying, incretin hormone secretion, and postprandial glycaemia in cystic fibrosis – effects of pancreatic enzyme supplementation. (Submitted for publication)

Kuo P, Wishart JM, Bellon M, Smout AJ, Holloway RH, Fraser RJ, Horowitz M, Jones KL, Rayner CK. Effects of physiological hyperglycaemia on duodenal motility and flow events, glucose absorption, and incretin hormone secretion in healthy humans. (Submitted for publication)

Kuo P, Chaikomin R, Bellon M, Jones KL, Horowitz M, Rayner CK. Validation of ^{14}C -3-O-methylglucose as a measure of intestinal glucose absorption in humans. (Submitted for publication)